Algae4IBD (101000501)

  https://cordis.europa.eu/project/id/101000501

  Horizon 2020 (2014-2020)

  ALGAE4IBD –FROM NATURE TO BEDSIDE- ALGAE BASED BIO COMPOUND FOR PREVENTION AND TREATMENT OF INFLAMMATION, PAIN AND IBD

  Prospecting aquatic and terrestrial natural biological resources for biologically active compounds (FNR-11-2020)

  public health  ·  inflammatory diseases  ·  phycology  ·  inflammatory bowel disease  ·  ecosystems

  2021-06-01 Start Date (YY-MM-DD)

  2025-05-31 End Date (YY-MM-DD)

  € 7,499,520 Total Cost

  Description

Algae4IBD's mission is to develop commercial products for Inflammatory Bowel Disease (IBD) prevention and treatment using aquatic natural biological resources. With the emerging developments in natural product, notable success has been achieved in discovering natural products and their synthetic structural analogues with anti-inflammatory activity. However, global biodiversity remains a largely unexploited resource for natural bioactive molecules with an enormous potential for developing commercial products with public health benefits. Micro and macroalgae, found in marine and freshwater, have been identified as promising sources of bioactive compounds including small molecules and secondary metabolites with a wide range of bioactivities as an antioxidant, anti-inflammatory and cancer preventive. Consumption of algae could, therefore, provide defence against chronic inflammatory diseases such as IBD, that until date have no effective cure. This project offers nature to bedside approach, using an entire development along the value chain for a new biodiscovery therapeutic approach by developing and examining algae-based compounds for IBD patients while guaranteeing algae's biodiversity preservation. We propose innovative solutions for increasing the use of algae-based ingredients and to ensure the science-based improvement of nutritional quality and its effect on public health. The researchers, companies and hospitals involved in the different stages of the project will use the biodiversity of algae, both micro and macro, as a wide source for bioactive compounds using state-of-the-art cultivation and extraction technologies for obtaining sufficient amounts of the bio-active molecules together with novel processing protocols. It will result in novel algal-based, high-quality bioactive compounds at GMP grade and lower costs for dual purposes – IBD prevention and treatment in relevance to the food as well as the pharmaceutical industries.

  Complicit Organisations

2 Israeli organisations participate in Algae4IBD.